Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-24. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Demonstrated 42.7% UACR reduction de-risks pivotal Phase II/III AMPLITUDE study approval, securing VRTX's non-CF revenue diversification pipeline.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factVertex Pharmaceuticals reported positive Phase IIb AMPLIFIED trial data for inaxaplin in APOL1-mediated kidney disease (AMKD). |
| What else was confirmed? | Reported factInaxaplin reduced urinary albumin-to-creatinine ratio (UACR) by 42.7% in AMKD patients with modest proteinuria. |
| Does the valuation support acting? | Interpretation3 stored valuation assumptions for VRTX; the latest is dated 2026-08-19. |
| What would change the assessment? | UnknownAMPLITUDE Trial Progress Updates — Management commentary on AMPLITUDE pivotal study dosing and readout timing |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Vertex Pharmaceuticals reported positive Phase IIb AMPLIFIED trial data for inaxaplin in APOL1-mediated kidney disease (AMKD).
- · Inaxaplin reduced urinary albumin-to-creatinine ratio (UACR) by 42.7% in AMKD patients with modest proteinuria.
- · Inaxaplin reduced UACR by 17.3% in patients presenting with both AMKD and type II diabetes.
- · Vertex has completed patient enrollment in the Phase II/III AMPLITUDE pivotal study.
Public research record
Research framework · page evidenceCompleted event assessment
pipeline net present value addition on AMKD clinical validation
| Type | Claim | Scope |
|---|---|---|
| Assumption | Vertex Pharmaceuticals reported positive Phase IIb AMPLIFIED trial data for inaxaplin in APOL1-mediated kidney disease (AMKD). | 2026-09-24 |
| Interpretation | pipeline net present value addition on AMKD clinical validation | VRTX |
Countercase, invalidators, and sources
AMPLITUDE pivotal readout confirms durable UACR reduction above 40%, unlocking an accelerated FDA regulatory submission pathway.
- · AMPLITUDE Trial Progress Updates — Management commentary on AMPLITUDE pivotal study dosing and readout timing
- Vertex Posts Positive Phase II Data on Kidney Disease Drug · 2026-09-23
What remains unresolved
- Base path
- VRTX absorbs the positive Phase IIb data as valuation shifts to timeline execution for AMPLITUDE pivotal Phase II/III completion.
- Adverse path
- Sub-group efficacy variations in diabetic cohorts prompt regulators to require expanded Phase III follow-up windows.
- Supportive path
- AMPLITUDE pivotal readout confirms durable UACR reduction above 40%, unlocking an accelerated FDA regulatory submission pathway.
- · AMPLITUDE Trial Progress Updates — Management commentary on AMPLITUDE pivotal study dosing and readout timingnext month
Evidence
- Vertex Posts Positive Phase II Data on Kidney Disease Drug2026-09-23
“Vertex Pharmaceuticals reported positive results from its phase IIb AMPLIFIED study, showing that inaxaplin reduced UACR by 42.7% in AMKD patients with modest proteinuria and 17.3% in those with AMKD and type II diabetes. The company has completed enrollment in the phase II/III AMPLITUDE pivotal study.”
Supports: Inaxaplin reduced UACR by 42.7% in AMKD patients and 17.3% in AMKD+T2D; completed enrollment in AMPLITUDE trial.